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Abstract
Background: Aggregation of peptide hormone precursors in the trans-Golgi network is an essential process in the
biogenesis of secretory granules in endocrine cells. It has recently been proposed that this aggregation corresponds
to the formation of functional amyloids. Our previous finding that dominant mutations in provasopressin, which
cause cell degeneration and diabetes insipidus, prevent native folding and produce fibrillar aggregates in the
endoplasmic reticulum (ER) might thus reflect mislocalized amyloid formation by sequences that evolved to
mediate granule sorting.
Results: Here we identified two sequences responsible for fibrillar aggregation of mutant precursors in the ER: the N-
terminal vasopressin nonapeptide and the C-terminal glycopeptide. To test their role in granule sorting, the glycopeptide
was deleted and/or vasopressin mutated to inactivate ER aggregation while still permitting precursor folding and ER exit.
These mutations strongly reduced sorting into granules and regulated secretion in endocrine AtT20 cells.
Conclusion: The same sequences — vasopressin and the glycopeptide — mediate physiological aggregation of the
wild-type hormone precursor into secretory granules and the pathological fibrillar aggregation of disease mutants in the
ER. These findings support the amyloid hypothesis for secretory granule biogenesis.
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Background
The peptide hormone vasopressin regulates water
homeostasis by binding to receptors of the renal collect-
ing duct to promote increased water reabsorption from
the urine. Absence of vasopressin causes diabetes insipi-
dus (DI), a disease characterized by loss of large
amounts of unconcentrated urine and increased thirst.
The hormone is synthesized by vasopressinergic neurons
in the hypothalamus as part of a precursor protein (pro-
vasopressin; illustrated in Fig. 1a) composed of a cleav-
able signal for endoplasmic reticulum (ER) targeting, the
nonapeptide hormone sequence, the 93-amino acid neu-
rophysin II (NPII) domain, and a glycopeptide of 39 resi-
dues of unknown function. The folded precursor is
stabilized by seven disulfide bonds in NPII and one in
the vasopressin sequence. Crystal structures show
vasopressin to fold with its N-terminus into a binding
pocket of NPII [1], which is essential for NPII folding
and export of the precursor from the ER [2].
Folded provasopressin is transported through the Golgi
to the trans-Golgi network (TGN) and sorted into dense-
core secretory granules, where it is cleaved by prohor-
mone convertases into its three constituents and where
the 10-amino acid vasopressin sequence CYFQNCPRGG
is converted to the C-terminally amidated nonapeptide
hormone CYFQNCPRG-NH2. The granules are trans-
ported to nerve terminals in the posterior pituitary for
regulated release. While the detailed mechanism of pro-
protein sorting into granules is not established, it is clear
that self-aggregation of regulated cargo at the TGN con-
tributes to granule formation [3–6]. Indeed, expression of
provasopressin (or of other regulated cargo proteins) was
shown to be sufficient to produce dense granule-like
structures in fibroblasts and other cells lacking endocrine-
specific machinery [7].* Correspondence: martin.spiess@unibas.chBiozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel,
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More than 70 different mutations causing familial
DI have been identified throughout the precursor se-
quence, except the glycopeptide. Most strikingly, all
but one of them are dominant, causing what is
known as autosomal dominant neurohypophyseal DI
(ADNDI). Patients who are heterozygous lack vaso-
pressin and develop DI gradually within months or
years after birth. Postmortem biopsies revealed the
loss of vasopressinergic neurons (see, e.g., [8–10]),
suggesting that mutant provasopressin causes their
degeneration. This phenotype was reproduced in
knock-in mouse models, where expression of the hu-
man DI mutant C67X (codon for cysteine 67 of NPII
mutated to a stop codon) led to progressive loss of
vasopressinergic neurons [11, 12]. In transfected cell
lines, mutant proteins were found to be retained in
the ER [13] and to some extent degraded via cyto-
plasmic proteasomes [14], as expected for polypep-
tides that are unable to fold. Most interestingly,
ADNDI mutant precursors were found to form fi-
brillar aggregates in the ER of transfected cells and
the purified mutant protein was shown to form fi-
bers in vitro [15]. These results suggested that
ADNDI belongs to the group of neurodegenerative
diseases associated with fibrillar protein aggregation,
similar to the amyloid diseases, with the distinction
that aggregation does not occur in the cytosol or ex-
tracellularly, but in the ER lumen. Analysis in mice
showed that aggregates produced by mutant precur-
sors induce autophagy-associated cell death [12].
Provasopressin thus contains sequences with the po-
tential to form pathological aggregates when mutations
interfere with native folding of the precursor. Such se-
quences may in fact have a physiological role. In a recent
study, it was proposed that aggregation of peptide hor-
mones into secretory granules corresponds to the forma-
tion of functional amyloids [16]. This was mainly based
on the observation that secretory granules of the
Fig. 1 Pro/Gly scan through full-length provasopressin suggests more than one ER aggregating segment. a Domain organization of preprovasopressin.
Cysteines are indicated by red dots, disulfide bonds by red lines, and glycosylation by a black diamond. Dots above the sequence indicate distinct mutations
causing autosomal dominant neurohypophyseal DI (missense or deletion in black, nonsense or frameshift in pink). The natural mutants used in this study,
ΔE47 and C61X, are labeled. The scale indicates the number of the amino acids in provasopressin. In constructs Pro1–Pro10 successive segments of 10
residues in provasopressin were replaced by proline/glycine-rich sequences as illustrated. b The constructs were expressed in HN10 cells for 2 days and
analyzed by immunofluorescence staining. Pro1/2/7/9-expressing cells are shown as examples. Nuclei were stained with DAPI (blue). Bar: 10 μm. c The
fraction of expressing cells with ER aggregates was quantified and plotted (mean and individual values of three or four independent transfections
(as indicated), analyzing ~200 expressing cells per transfection as described in “Methods”). d Immunoblot analysis of transfected cells after separation by
reducing sodium dodecyl sulfate (SDS)-gel electrophoresis is shown. Considerable amounts of SDS- and dithiothreitol-resistant provasopressin oligomers
were detected for all proteins except Pro1. Molecular weight standards are indicated in kilodaltons
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pituitary — including those containing vasopressin —
stained positive for thioflavin S, and that many ma-
ture peptide hormones — including vasopressin —
could form fibrils in vitro. In this light, the formation
of pathological aggregates in the ER of folding-
deficient provasopressin may be a consequence of a
physiological aggregation motif that evolved for the
formation of functional amyloids in the TGN. To test
this hypothesis, it is important to identify the se-
quence motifs responsible for both pathological aggre-
gation in the ER and physiological aggregation of the
natively folded precursor into granules at the TGN.
Previous analyses did not allow a clear conclusion on
the sequences required for granule sorting. Using
green fluorescent protein (GFP) fusion constructs,
residues 1–27 of provasopressin, but not 1–10 (the
hormone sequence) or 13–27 (the N-terminus of
NPII) alone, were reported to mediate granule
localization in one study [17] and the NPII domain in
another [18]. In general, identification of signals for
sorting or aggregation into the secretory granules has
not been very successful, to a large extent because
mutagenesis of precursor proteins frequently results
in misfolded products retained in the ER.
Here we first identified by scanning mutagenesis
and deletion analysis two independent segments re-
sponsible for ER aggregation: the nonapeptide hor-
mone sequence and the glycopeptide. Analysis of
folding-competent precursor proteins mutated in
these segments indicates that the same sequences also
mediate granule aggregation and sorting. These find-
ings thus support the hypothesis that, in ADNDI, se-
quences that have evolved to physiologically aggregate
the folded protein at the TGN cause premature aggre-
gation of folding-incompetent mutant proteins in the
ER with toxic effects to the cell.
Results
To analyze the aggregation properties of wild-type and
mutant vasopressin precursors, we expressed them in
HN10 neuroblastoma cells, which were cultured in differ-
entiation medium to induce the formation of neuronal
processes. By immunofluorescence microscopy, wild-type
provasopressin was detected in secretory granules as fine
puncta located mostly in the cellular processes and local-
izing with the granule marker chromogranin A (CgA;
Additional file 1: Figure S1, filled arrowheads). In contrast,
the natural ADNDI mutant ΔE47 accumulated in most of
the cells in larger aggregations within the cell body which
were costained with antibodies directed against the KDEL
ER retention motif (open arrowheads), in agreement with
our previous observation of ER aggregations in COS and
Neuro2A cells [15].
Provasopressin contains more than one aggregating
sequence
To identify the sequence motif(s) necessary to form fi-
brillar aggregates of misfolded provasopressin, mutant
constructs Pro1–Pro10 were produced with a 10-residue
long proline-/glycine-rich sequence scanning through
the first 100 amino acids of provasopressin (vasopressin
and NPII), as illustrated in Fig. 1a. Prolines and glycines
disrupt secondary structures, particularly β-sheets, the
essential element of amyloids. The sequence
PGPGPGTPGP was used to replace each segment of 10
amino acids in the vasopressin and NPII portions of the
full-length protein. For Pro1 the first two residues were
swapped (GPPGPGTPGP) to allow signal cleavage,
which is prevented by proline at the cleavage site. All 10
constructs also disrupt precursor folding.
Surprisingly, all Pro/Gly mutant provasopressins
were found to aggregate efficiently in the ER of ex-
pressing HN10 cells (Fig. 1b and c). No single 10-
amino acid segment of vasopressin-NPII is thus ne-
cessary for ER aggregation, and there must be more
than one segment in provasopressin sufficient to
cause aggregation. When transfected cells were lysed
without reduction and analyzed by immunoblotting
after nonreducing sodium dodecyl sulfate (SDS)-gel
electrophoresis, the accumulated intracellular mutant
proteins did not enter the separating gel, suggesting
that they aggregated in a highly disulfide-linked form.
Upon addition of 100 mM dithiothreitol (DTT) and
boiling, they entered the separating gel, but all mu-
tant constructs except Pro1 were detected to a large
extent as SDS/DTT-resistant homo-oligomers, typical
of some amyloid aggregates (Fig. 1d).
The shortest known pathogenic provasopressin mutant
forms fibrillar aggregates in the ER
To reduce the complexity of the system, we focused on
the shortest known pathogenic ADNDI mutant, C61X,
in which the codon for Cys-61 in NPII is altered to a
stop codon. The protein thus corresponds to the N-
terminal half (residues 1–72) of the precursor. Since our
antibody does not recognize this part of the protein, a
myc-tagged version of C61X, C61myc (Fig. 2a), was
expressed in HN10 cells and found to produce aggre-
gates positive for the ER chaperone calreticulin in the
majority of expressing cells (Fig. 2b and c) as well as
SDS/DTT-resistant oligomers (Fig. 2d). By electron mi-
croscopy (Fig. 2e), these aggregates, as identified by
immunogold labeling, appeared to be made up of a net-
work of fibrils similar to those formed by full-size mu-
tant provasopressin [15]. At least one aggregate-forming
element thus resides within the N-terminal 72 residues
of provasopressin. In addition, the correlation between
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aggregation and pathogenicity is supported by this short-
est DI mutant.
Provasopressin deletion constructs further trun-
cated to the N-terminal 60 or 50 residues and fused
to a myc epitope still produced large aggregates de-
tectable by immunofluorescence (Fig. 2b and c), in-
dicating that an aggregating sequence is located within
the N-terminal 50 residues. A further truncation mutant, 1-
40myc, could not be detected by immunofluorescence
microscopy of transfected cells, most likely because the
protein was too short for cotranslational translocation and
was rapidly degraded in the cytosol.
The vasopressin segment is necessary for aggregation of
provasopressin 1–75 and sufficient for ER aggregation of
a reporter protein
The Pro/Gly scan was now repeated for the N-terminal
half of provasopressin (residues 1–75) alone, as
Fig. 2 ER aggregation of C-terminally truncated forms of provasopressin. a Schematic representation of C-terminally truncated provasopressin mutants
C61myc (corresponding to 1-72myc), 1-60myc, and 1-50myc. The myc epitope is shown in purple. b These constructs were expressed in HN10 cells and
visualized by immunofluorescence microscopy. Cells expressing C61myc were costained for the ER chaperone calreticulin. Nuclei were stained with DAPI
(blue). Bar: 10 μm. c The fraction of expressing cells with ER aggregates was quantified and plotted (mean and individual values of four independent
transfections, analyzing ~200 expressing cells per transfection). d Immunoblot analysis of untransfected cells (−) and transfected cells expressing C61myc
after reducing SDS-gel electrophoresis. Molecular weight standards are indicated in kilodaltons. e Electron micrographs of C61myc aggregates forming a
fibrillar network decorated with 10-nm gold. The surrounding rough ER membrane is visible in the left micrograph. Bars: 200 nm. Below, a section is shown
enlarged with and without fibrillar lines highlighted for clarity
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illustrated in Fig. 3a. Of the seven constructs, only 1–
75Pro1 did not produce ER aggregates in the vast
majority of expressing cells (Fig. 3b and c). Again, the
Pro1 mutation was the only one not generating SDS-
and DTT-resistant homo-oligomers (Fig. 3d). These
results show that a single 10-amino acid segment at
the very N-terminus of the protein is necessary for
aggregation. This segment corresponds to the vaso-
pressin hormone sequence.
To define the sequence sufficient for aggregation, N-
terminal segments of preprovasopressin were fused to a
reporter polypeptide (Rep) consisting of a fragment of
glutathione S-transferase (GST; residues 101–218) that
cannot fold and is thus retained in the ER. Construct 1–
Fig. 3 The vasopressin nonapeptide is necessary for ER aggregation of provasopressin 1–75 and sufficient to aggregate a reporter construct. a Schematic
presentation of provasopressin 1–75 (with a C-terminal His6 tag in black) and its proline/glycine scanning mutants 1–75Pro1–7. b Immunofluorescence
localization of example constructs expressed in HN10 cells. The indicated constructs fused to a His6 tag were transfected into HN10 cells and fluorescently
stained using an anti-His6 antibody. Bar: 10 μm. c Aggregation frequency of these constructs was quantified as before (mean and individual values of four
independent transfections, analyzing ~200 expressing cells per transfection). d Transfected cells were lysed, separated by reducing SDS-gel electrophoresis,
and subjected to immunoblot analysis to detect intracellularly accumulated provasopressin constructs. Molecular weight standards are indicated in
kilodaltons. e Truncated provasopressin sequences 1–75 (positive control), 1–75Pro1 (negative control), 1–50, 1–25, 1–16, and 1–10 were fused to a reporter
sequence (Rep) consisting of the C-terminal fragment 101–218 of glutathione S-transferase (GST, orange) with a myc epitope (in purple). f Immunofluores-
cence localization of indicated constructs expressed in HN10 cells. Bar: 10 μm. g Aggregation frequency of the constructs shown in panel e was quantified
as before (mean and individual values of three independent transfections for 1–75-Rep, 1–75Pro1-Rep, and 1–10-Rep, and single determinations for the
others, analyzing ~100 expressing cells per transfection)
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75-Rep, in which the signal sequence and residues 1–75
of provasopressin were fused to the reporter, aggregated
in approximately 50% of expressing HN10 cells, i.e.,
somewhat less than 1–75 alone. As expected, 1–75Pro1-
Rep did not significantly aggregate at all (Fig. 3e–g). C-
terminally truncated provasopressin segments corre-
sponding to the N-terminal 50, 25, 16, and 10 residues
all still produced intracellular aggregates. The vasopres-
sin sequence CYFQNCPRGG is thus not only necessary,
but also sufficient to cause aggregation of a polypeptide.
The glycopeptide mediates fibrillar aggregation of
provasopressin in the absence of the hormone sequence
To localize the additional aggregating sequence(s) in
provasopressin, the first three Pro/Gly mutations (Pro1/
2/3) were analyzed in the context of the full-size protein,
of a truncated version lacking the C-terminal glycopep-
tide segment (Δgp), and of the N-terminal 75 residues
(1–75, fused to a His6 tag; Fig. 4a). Deletion of the glyco-
petide dramatically reduced aggregation in the context
of the Pro1 construct, but not Pro2 or Pro3 (Fig. 4b and
Fig. 4 The glycopeptide sequence contains a second aggregation sequence. a Full-size provasopressin and deletion mutants lacking the glycopeptide
(Δgp) or the C-terminal half of the protein (1–75), with or without the ΔE47 point mutation or the Pro1, Pro2, or Pro3 replacement (as indicated) were
constructed to localize the second aggregation sequence. The truncated proteins were provided with a His6 tag (black bar). b Constructs were expressed
in HN10 cells and analyzed by immunofluorescence as shown for selected examples. Bar: 10 μm. c The fraction of expressing cells forming ER aggregates
was quantified as before (mean and individual values of three or four independent transfections (as indicated), analyzing ~200 expressing cells per
transfection). For comparison, values for Pro1/2/3, 1–75, and 1–75Pro1/2/3 from Figs. 1c and 3c, respectively, are also shown. d, e Cells expressing construct
Pro1, which lacks the N-terminal aggregation sequence, were analyzed by electron microscopy with immunogold labeling. Aggregates formed via the
glycopeptide sequence showed different degrees of compaction (see also Additional file 2: Figure S2). Some aggregates contained dense and light regions
(d), while others were almost completely dense (e). Bars: 500 nm. Enlargements of the boxed regions below reveal a fibrillar network within the aggregates
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c). The glycopeptide thus contains an independent ag-
gregating activity. Gradual C-terminal deletion of the
glycopeptide resulted in a progressive reduction of ER
aggregation (Fig. 5).
When analyzed by electron microscopy, provasopres-
sin mutants Pro1 and Pro1ΔE47 lacking the hormone
sequence, but containing the glycopeptide, were found
in aggregations made up of a network of fibers (Fig. 4d
and e, and Additional file 2: Figure S2). In some aggre-
gate structures, the network formed regions of higher
and lower density, which were also decorated by immu-
nogold labeling to a larger and smaller extent, respect-
ively (Fig. 4d and Additional file 2: Figure S2A and C).
In other cases, the dense regions appeared to coalesce or
even fill the structures entirely (Fig. 4e and Additional
file 2: Figure S2B and D).
A vasopressin mutant deficient in ER aggregation but
permissive of precursor folding
To test the role of the glycopeptide in granule sorting, it
can simply be deleted, since this segment is not required
for vasopressin–NPII folding and ER exit. To test the
contribution of the vasopressin segment in granule sort-
ing is more difficult, since its interaction with NPII is re-
quired for folding. We aimed at generating a mutant
vasopressin sequence that has lost its ability to aggregate
in the ER, but still allows precursor folding and ER exit,
and thus can be tested for granule sorting. The crystal
structure of vasopressin bound to NPII (1JK4 [1]) shows
that the N-terminus, C1 and C6 with their disulfide
bond, as well as Y2 are buried inside NPII (illustrated in
Additional file 3: Figure S3) and thus are essential for
precursor folding. The side chains of F3, Q4, N5, P7,
and R8 appear to be exposed to the solvent. We there-
fore mutated the vasopressin sequence CYFQNCPRG to
CYAAACAAG in the context of the full-size precursor
(V5xA), of a construct lacking the glycopeptide
(V5xAΔgp), and as a truncated and thus folding-
incompetent mutant (1–75V5xA). Expression of 1–
75V5xA produced significantly fewer cells with aggre-
gates than construct 1–75 with the wild-type vasopressin
sequence, although more than 1–75Pro1 (Fig. 6a). The
V5xA mutations thus strongly reduce the proteins’ abil-
ity to aggregate in the ER, but do not completely elimin-
ate it. Similarly, the amount of SDS- and DTT-resistant
cellular oligomers was clearly reduced by the 5xA muta-
tions (to ~35%, compared to ~75% for 1–75 and a back-
ground level ~20% for 1–75Pro1), but again not entirely
abolished (Fig. 6b).
To assess whether the fivefold alanine mutation allows
precursor folding, constructs V5xA and V5xAΔgp were
expressed in HN10 cells in parallel with the correspond-
ing proteins with wild-type vasopressin and with the
folding-deficient mutant ΔE47. Upon 30 min of pulse
Fig. 5 Deletion analysis of the glycopeptide with respect to ER aggregation. a Several amyloid prediction programs (including Aggrescan [42],
Amylpred [43], and FoldAmyloid [44]) pointed to the sequence 120–129 in the middle of the glycopeptide sequence as potentially amyloidogenic. In
construct Pro1Δ120-9, this sequence was deleted. In addition, the glycopeptide was gradually truncated from the C-terminus in Pro1Δgp10/20/30. b
Formation of aggregates in transfected HN10 cells revealed no significant effect of deleting the central sequence, but a gradual reduction of aggregate
formation upon C-terminal truncation. The mean and individual values of two to four independent transfections (as indicated), analyzing ~200
expressing cells per transfection, are shown
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labeling with [35S]methionine/cysteine (Fig. 6c), the full-
length constructs were produced mostly as glycosylated
and to a lesser extent as unglycosylated protein (as ob-
served previously [15]). During a subsequent 2-h chase,
ΔE47 was entirely retained in the cell. In contrast, all
other mutant proteins, except the unglycosylated full-
length products, were secreted with similar efficiency as
wild-type provasopressin, indicating that the V5xA mu-
tant vasopressin to a significant extent was able to fold
with NPII and thus also to form the disulfide bond be-
tween C1 and C6. The pulse-chase experiment also
shows that HN10 cells inefficiently process the precur-
sors, since the majority of wild-type and V5xA was re-
leased as full-length protein still containing the
glycopeptide. No processed precursor even of the wild-
type protein was detected within the cells after the
chase, suggesting that storage in granules is low in
HN10 cells.
The vasopressin and glycopeptide segments also mediate
sorting into secretory granules
To investigate granule sorting of wild-type provasopres-
sin and the V5xA, Δgp, and double mutants in a quanti-
tative manner, we generated stable expressing cells in
the mouse pituitary corticotropic cell line AtT20, which
is frequently used to study regulated prohormone secre-
tion. Pulse labeling with [35S]methionine/cysteine for
30 min showed similar expression levels of the different
constructs except for V5xA, which was produced at al-
most twice the amount (Fig. 7a). After a subsequent 2 h-
chase, however, similar amounts of processed NPII were
secreted from all cell pools, even of V5xA, suggesting
that a fraction of this protein was retained in the ER.
Consistent with this interpretation, unprocessed full-
length forms of V5xA were still detectable in the cell lys-
ate. While V5xA is capable of precursor folding and ER
exit, it appears to be less efficient than for wild-type
vasopressin in AtT20 cells.
By immunofluorescence microscopy using an NPII-
specific antibody, wild-type provasopressin was found
clearly concentrated in granules in the cellular exten-
sions together with endogenous CgA as a granule
marker (Fig. 7b). Separate 5xA mutation of vasopressin
(Fig. 7c) or deletion of the glycopeptide (Fig. 7d) did not
abolish apparent concentration in granules. In contrast,
the double mutant V5xAΔgp was clearly reduced and
frequently almost absent in granules (Fig. 7e).
Quantitation of provasopressin intensity in CgA-
positive granules normalized to CgA content (Fig. 7f,
gray) confirmed that deletion of the glycopeptide
alone did not notably diminish accumulation in
granules. Mutation of vasopressin, however, pro-
duced a significant reduction that was further en-
hanced in the double mutant. This suggests that
both vasopressin and the glycopeptide contribute to
sorting into granules, which is most strongly reduced
when both domains are inactivated. For a more
quantitative assessment of these contributions, the
fluorescence values should be normalized to the
levels of each protein reaching the TGN. Because ER
exit of V5xA and probably also V5xAΔgp is less effi-
cient than that of wild-type precursor and Δgp, re-
spectively (Fig. 7a), the levels of protein synthesis
are not useful. Instead, we used the relative amounts
of protein recovered after 2 h of chase — secreted
into the medium and still present within the cells —
when most ER-retained material had been degraded,
as a better approximation to the amount of protein
that exited the ER and passed through the TGN in
the four cell lines. The result of this normalization is
shown in Fig. 7f (black) and confirms the conclusion
that both vasopressin and glycopeptide contribute to
granule sorting.
Fig. 6 V5xA mutation reduces ER aggregation while still permitting
precursor folding and secretion. a The fraction of cells expressing
1–75, 1–75Pro1, or 1–75V5xA forming ER aggregates was quantified
as before (mean and individual values of three independent
transfections, analyzing ~100 expressing cells per transfection). All
pairwise comparisons are significantly different according to an
unpaired two-tailed t test (**p < 0.01; ***p < 0.001). b Transfected
cells were lysed, separated by reducing SDS-gel electrophoresis, and
subjected to immunoblot analysis to detect intracellularly accumulated
provasopressin constructs. Molecular weight standards are indicated
(in kilodaltons). c Transfected HN10 cells expressing the indicated
provasopressin constructs were labeled with [35S]methionine for
30 min and chased for an additional 2 h. From cell lysates and media,
products were immunoprecipitated and analyzed by gel electrophoresis
and autoradiography. The positions of full-size glycosylated (FLg) and
unglycosylated forms (FLu) and of constructs without glycopeptide (Δgp)
are indicated
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Stimulated secretion depends on vasopressin and
glycopeptide
As a functional test for sorting into the regulated
secretory pathway, we assessed the stimulated release of
wild-type and mutant provasopressins from the stable
AtT20 cell lines. This approach is largely independent of
protein levels at the TGN. Proteins released from the dif-
ferent AtT20 cell lines were collected from the media be-
fore and after stimulation with BaCl2, corresponding to
constitutive and stimulated secretion, respectively [19, 20],
and analyzed by gel electrophoresis and immunoblotting.
Release of wild-type and V5xA precursors were similarly
stimulated more than tenfold above constitutive levels,
whereas the effect of stimulation on secretion of the pre-
cusors lacking the glycopeptide was strongly reduced,
most significantly for the double mutant V5xAΔgp (Fig. 8).
As a negative control, stable transfected AtT20 cells ex-
pressing α1-protease inhibitor (A1Pi), a constitutive
secretory protein, were analyzed. Stimulated secretion was
even lower than for the double mutant, consistent with
the notion that V5xA mutation still retains residual aggre-
gation activity. Taken together the results show that both
Fig. 7 Granule sorting is mediated by both vasopressin and glycopeptide. a Stable AtT20 cells expressing the indicated provasopressin constructs
were labeled with [35S]methionine for 30 min and chased for an additional 2 h. From cell lysates and media, products were immunoprecipitated
and analyzed by gel electrophoresis and autoradiography. The positions of full-size glycosylated (FLg) and unglycosylated forms (FLu) and of
constructs without glycopeptide (Δgp) are indicated. b–e AtT20 cells stably expressing wild-type provasopressin (wt) or the mutants without the
glycopeptide (Δgp) or with the V5xA mutant hormone sequence (5xA) or both (5xAΔgp) were stained for CgA as a granule marker, NPII, and nuclei
(blue). Granules concentrate in terminal patches. Bar: 10 μm. f Quantitation of NPII staining in granule patches normalized for content of CgA.
NPII/CgA ratios of ~70 images per construct (45 images for untransfected AtT20 cells, −) containing 4–5 cells each are summarized as a box plot
showing the median and the center 50% of values in the box, with the whiskers including the 10th to the 90th percentiles. The central dot
represents the mean. The original quantitation is shown on the left in gray and white. In black and gray, the data are shown upon correction for
the relative amounts of pulse-labeled protein recovered from both media and cell lysates after a 2-h chase (three independent experiments
including that shown in panel a; wt, 1.0; V5xA, 0.77 ± 0.20; Δgp, 0.78 ± 0.20; V5xAΔgp, 0.68 ± 0.19). All pairwise comparisons, except wild-type vs.
VΔgp, are significantly different according to an unpaired two-tailed t test (p < 0.001). The most important ones are indicated above the graph
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sequences causing ER aggregation of folding-deficient pro-
vasopressin mutants are also responsible for granule sort-
ing of the wild-type protein. This supports the notion that
pathological ER aggregation of DI mutants is the result of
sequences that evolved to mediate granule sorting.
Discussion
Peptides or proteins that form amyloid aggregates in
vivo have long been associated exclusively with disease.
In recent years, however, an increasing number of pro-
teins have been discovered to produce functional amy-
loids for physiological purposes [21, 22], such as
Escherichia coli curli for biofilm formation [23] or hu-
man Pmel17 to organize melanin in melanosomes
[24]. Maji et al. [16] provided evidence suggesting
that peptide hormones are concentrated in secretory
granules as functional amyloids. In circumstantial
support for this notion, it has previously been noted
that polypeptide hormones are over-represented
among the proteins known to form amyloid fibers in
human disease [25], including for example amylin
(islet amyloid polypeptide), calcitonin, and atrial natri-
uretic factor. Provasopressin also belongs to this
group, since DI mutants produce fibrillar aggregates
in the ER [15] and cause cell degeneration in vivo
[10–12]. This correlation suggested that sequences
that have evolved for physiological aggregation in
granule biogenesis may be responsible for pathological
aggregations under certain conditions. We have tested
this concept in the case of provasopressin by identify-
ing the sequences causing ER aggregation of misfold-
ing mutants and testing their contribution to granule
sorting and regulated secretion.
Our search for the segments in provasopressin that
cause fibrillar ER aggregation surprisingly identified two
separate and independent sequences: the N-terminal
vasopressin nonapeptide and the C-terminal glycopep-
tide. Several nonsense DI mutants lack the glycopeptide
and thus aggregate only via vasopressin, indicating that
this type of aggregation can cause dominant disease.
Whether aggregation via the glycopeptide alone is cyto-
toxic in vivo is not known. Three dominant DI muta-
tions altering the vasopressin sequence have been
identified [26–28], but it is unknown whether they abol-
ish the ability of the hormone sequence to aggregate in
the ER.
The large variety of more than 70 different known
ADNDI mutations throughout the sequence of vaso-
pressin and NPII strongly suggests that the common
mechanism to cause disease is to prevent native fold-
ing of the precursor, which results in retention and
accumulation in the ER. At the same time, the vaso-
pressin sequence remains exposed and is able to form
fibrillar aggregates that are further crosslinked by
intermolecular oxidation of the large number of cyste-
ines in NPII. In the absence of the hormone segment,
aggregation still occurs via the glycopeptide. We ob-
served previously that provasopressin with all its 16
cysteines mutated to serines was unable to aggregate
[15]. One can thus conclude that under ER conditions
aggregation by the glycopeptide requires stabilization
by intermolecular disulfide crosslinks. Consistent with
this general mechanism, no DI mutations have been
found within the sequence of the glycopeptide, since
they would not affect folding of vasopressin–NPII.
The four different DI mutations in the signal peptide
were shown to inhibit signal cleavage (see, e.g., [13]).
As a result, the uncleaved signal again prevents
Fig. 8 Stimulated secretion depends on both vasopressin and
glycopeptide. a AtT20 cells stably expressing wild-type provasopressin
(wt) or the mutants without the glycopeptide (Δgp) or with the V5xA
mutant hormone sequence (5xA) or both (5xAΔgp), or expressing the
constitutive secretory protein A1Pi were grown and incubated for
30 min each with serum-free medium without (−) and then with BaCl2
(+) to stimulate granule secretion for 30 min each. The media were
collected, concentrated, and analyzed by SDS-gel electrophoresis and
immunoblotting. To keep intensities within the diagnostic range of
immunoblot analysis, a threefold larger aliquot (3x) of the control
medium was analyzed than of the stimulation medium (1x). b Immuno-
blots as in A were quantified and stimulated secretion plotted as the ratio
of stimulated to constitutive secretion (s/c). The mean and the individual
values of four to five independent experiments are shown. Except for
wild-type vs. V5xA, all pairwise comparisons are significantly different
according to an unpaired two-tailed t test (the most important ones are
indicated above the graph; *p< 0.05; **p<0.01)
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protein folding, which requires a free N-terminus of
vasopressin to insert into a pocket in NPII.
Most importantly, the same two precursor segments
were also found to mediate granule sorting at the TGN
of endocrine cells. This finding supports the hypothesis
that the two aggregation processes in the ER and the
TGN are related. In the wild-type situation, the precur-
sor rapidly folds in the ER, whereby the vasopressin seg-
ment is concealed in its binding pocket in NPII, thus
preventing premature aggregation. The glycopeptide, on
the other hand, is unable to aggregate under ER condi-
tions without stabilizing crosslinks. Upon ER exit and
transport through the Golgi, the specific conditions in
the TGN promote aggregation. These include reduced
pH [29], high concentrations of Ca2+ and possibly other
divalent cations such as Zn2+ and Mg2+ [30, 31], and the
presence of glycosaminoglycans [32]. These conditions
may induce a conformational change in the precursor to
release vasopressin from its binding site on NPII. In
vitro, however, the binding affinity of vasopressin to
NPII was not reduced upon lowering the pH to 6 alone
[33]. Alternatively, facilitated aggregation of the hor-
mone may simply sequester it from the equilibrium be-
tween bound and free states of vasopressin into the
polymers. Similarly, the TGN conditions are likely to en-
hance the aggregating properties of the glycopeptide,
making its polymerization independent of stabilizing
crosslinks.
The original proposal by Maji et al. [16] that granules
constitute functional amyloids appears to conflict with
the notion of granules forming by aggregation of folded
proteins, since some free peptide sequence is required to
form the amyloid. In the case of provasopressin, this is
made possible by the glycopeptide, which is not part of
the main fold of vasopressin with NPII, and by the fact
that vasopressin may dissociate from NPII while
remaining tethered by the connecting loop containing
the convertase cleavage site. Pro-oxytocin is very closely
related to provasopressin (74% identity in the hormone–
NP sequence) except that it lacks a glycopeptide and is
thus very likely to aggregate in granule biogenesis simi-
larly via the hormone segment. Whether other prohor-
mones also employ peptide segments that are
conditionally releasable from a globular fold under TGN
conditions remains to be investigated. Alternatively,
unfolding of a globular protein may be required to form
amyloid aggregates, as has been proposed by Jacob et al.
[34] for growth hormone.
So far the evidence for the amyloid-like nature of
secretory granules is mainly based on in vitro aggrega-
tion experiments with peptide hormones. Evidence at
the cellular or tissue level is so far limited to staining of
pituitary granules with an amyloid-specific antibody,
with thioflavin T and Congo red, and to X-ray diffraction
patterns of purified granules consistent with the pres-
ence of cross-β structure [16, 34, 35]. The fibrillar ap-
pearance of the ER aggregates of provasopressin
mutants by EM suggests amyloid-like aggregation.
Secretory granules, in contrast, do not reveal such fibril-
lar morphology, but display a homogeneous appearance
[36], most likely because of denser packing of its cargo
compared to the fibers of unfolded, chaperone-bound
polypeptides in the ER.
Amyloids in a strict sense are cross-β-sheet polymers.
Because of the high curvature of its backbone, the cyclic
vasopressin peptide with its C1–C6 disulfide bond is un-
able to form a typical β-sheet. This may also explain why
we were unable to stain ER aggregates with thioflavin S
or the amyloid-specific antibody OC. One might specu-
late that an “imperfect amyloid” may be more rapidly
redissolved upon stimulated secretion. (In contrast, the
resistance of ER aggregates to complete disassembly is
most likely due to the extensive disulfide crosslinking by
cysteines of the misfolded NPII sequence.) Along the
same line, it was shown for somatostatin-14, another cir-
cular peptide hormone with a disulfide bond between
C3 and C14, that redissolution of in vitro fibrillar aggre-
gates was accelerated for the oxidized circular form in
comparison to that of the reduced linear form [35].
Chromogranins A and B, widespread secretory granule
cargos, also contain a disulfide-linked ring, albeit of 22
residues, in their N-terminal domain that was shown to
be required for granule sorting [37, 38]. Similarly, a 13-
residue disulfide ring was identified as a granule deter-
minant of pro-opiomelanocortin [39]. Disulfide rings
may thus constitute a more general structural device for
aggregation in the regulated secretory pathway.
Conclusions
Here we identified two sequences in the vasopressin pre-
cursor protein to independently cause fibrillar, amyloid-
like aggregation of folding-deficient mutants in the ER:
the N-terminal hormone sequence and the C-terminal
glycopeptide. They thus constitute the molecular basis
of the aggregates leading to autophagy-associated cell
death in dominant neurohypophyseal diabetes insipidus.
Our finding that the same amyloidogenic sequences that
cause pathogenic ER aggregation also confer granule
sorting and regulated secretion in AtT20 cells provides
biological support for the notion that secretory granules
are functional amyloids of peptide hormones.
Methods
Plasmids and constructs
The cDNAs of the human wild-type vasopressin precur-
sor and the mutants ΔE47 and a construct in which all
cysteines were replaced by serines have been described
before [13–15]. All other mutants were prepared by
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polymerase chain reaction (PCR) using mutagenic
primers. For the Pro/Gly scan, the sequence coding for
PGPGPGTPGP was generated at different positions by
PCR amplification of 5′ portions of the provasopressin
coding sequence using primers that added the 3′ exten-
sion CCAGGACCTGGACCTGGTACCGCG with an
Asp 718 site (underlined) and of 3′ portions adding the
5′ extension GCGTGTACACCAGGTCCA with a BsrGI
site. Matching products were cut with Asp 718 and
BsrGI, respectively, mixed, ligated by their compatible
ends, and amplified using the outside primers. Products
of the size of the correct fusion were isolated and cloned
into the expression plasmid. For construct Pro1, the first
two codons were swapped to encode the sequence
GPPGPGTPGP and to preserve signal cleavage. Codons
101–218 of GST from the plasmid pGEX-4T-2 (GE
Healthcare) C-terminally tagged with a myc epitope
were used as a reporter sequence and fused downstream
of codons 1–75/50/25/16/10 of provasopressin and of
1–75Pro1. All cDNAs were subcloned into the pRc/RSV
expression plasmid (Invitrogen) and confirmed by
sequencing.
Cell culture and transfection
The mouse hippocampal neuroblastoma cell line HN10
[40], which had been successfully used to study hunting-
tin aggregation [41], was grown in Dulbeccco’s modified
Eagle’s medium (DMEM) containing 4500 mg/l glucose,
supplemented with 10% fetal calf serum, 100 units/ml
penicillin, 100 μg/ml streptomycin, and 2 mM L-glutam-
ine at 37 °C in 5% CO2. Cells were transfected using
Fugene HD (Promega). To induce differentiation, cells
were cultured from 1 day after transfection in serum-
free DMEM containing B27 supplements and 6 μM ret-
inoic acid.
AtT20 cells were grown in DMEM containing
1000 mg/l glucose, supplemented with 10% fetal calf
serum, 100 units/ml penicillin, 100 μg/ml streptomycin,
2 mM L-glutamine at 37 °C in 7.5% CO2. Cells were
transfected with pRc/RSV encoding wild-type or mutant
preprovasopressin or pre-A1Pi using Fugene HD and se-
lected using 100 mg/ml G418 to select stably expressing
mixed cell pools.
Immunofluorescence
Transfected cells were grown for 48 h on glass cover-
slips, fixed with 3% paraformaldehyde for 30 min at
room temperature, washed in phosphate-buffered saline
(PBS), quenched 5 min in 50 mM NH4Cl in PBS, perme-
abilized in 0.1% Triton X-100 (Applichem) in PBS for
10 min, blocked with 1% bovine serum albumin (BSA,
Roche) in PBS for 15 min, incubated at room
temperature with primary antibodies for 2 h in BSA/
PBS, washed, stained with fluorescent secondary
antibodies in BSA/PBS for 30 min, and mounted in
Fluoromount-G (Hoechst) with 0.5 μg/ml DAPI. As pri-
mary antibodies, we used a self-made polyclonal rabbit
anti-provasopressin antiserum (raised against residues
28–145, i.e., the C-terminal portion of NPII and the gly-
copeptide), mouse monoclonal anti-myc antibody 9E10
(prepared from hybridoma, RRID:CVCL_L708, 1:100),
mouse monoclonal anti-His6 (HIS.H8, Millipore, 05–
949, Lot: 2426469, RRID:AB_492660, 1:2000), goat poly-
clonal anti-CgA (Santa Cruz, Sc-1488, Lot: H310, RRI-
D:AB_2276319, 1:50), rabbit anti-A1Pi (Neomarkers,
RB-367-A, Lot: 367A808B, RRID:AB_59584), and a
mouse monoclonal anti-KDEL antibody (MBL, SR-827F,
Lot: 12031335, RRID:AB_1279100, 1:500). As secondary
antibodies, non-cross-reacting A488-labeled donkey
anti-mouse (Molecular Probes, A21202, Lot: 1305303,
RRID:AB_141607, 1:400), A488-labeled donkey anti-
rabbit (Molecular Probes, A21206, Lot: 1674651, RRI-
D:AB_2535792, 1:400), A568-labeled donkey anti-goat
(Molecular Probes, A11057, Lot: 1235787, RRI-
D:AB_142581, 1:400), and A568-goat anti-mouse im-
munoglobulin antibodies (Molecular Probes, A11031,
RRID:AB_144696, 1:400) were used. Staining patterns
were analyzed using a Zeiss Confocal LSM700
microscope.
Aggregation was quantified by counting the fraction of
expressing cells containing punctate accumulations
using a Zeiss Axioplan microscope with a Leica
DFC420C imaging system. For each construct, ~200 ex-
pressing cells were counted in each of three independent
transfections.
To quantify localization of provasopressin constructs
with and without the glycopeptide to secretory granules,
the anti-provasopressin antiserum was depleted of anti-
bodies directed against the glycopeptide. For this, a
GST-glycopeptide fusion protein was expressed in
Escherichia coli Rosetta using the vector pGEX-4T-2 and
purified with glutathione Sepharose-4B (GE Healthcare)
according to the manufacturer’s instructions. Anti-
provasopressin-antiserum was incubated with GST-
glycopeptide bound to glutathione Sepharose-4B, and
the supernatant containing only anti-NPII antibodies
was tested for lack of reactivity with GST-glycopeptide
by immunoblotting.
Immunoblot analysis
Transiently transfected HN10 cells were scraped and
boiled in SDS sample buffer and stored frozen. Samples
were supplemented with or without 100 mM DTT, boiled,
separated on 10% polyacrylamide Tris/tricine SDS-gel
electrophoresis, and subjected to immunoblot analysis on
polyvinylidene difluoride (PVDF) membranes (Millipore)
using peroxidase-coupled secondary antibodies and the
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ECL (enhanced chemiluminescence) reaction kit
(Millipore).
Pulse-chase and immunoprecipitation
Transiently transfected HN10 cells or pooled stable
AtT20 cells were incubated for 30 min in starvation
medium (DMEM lacking methionine and cysteine)
and for 30 min in labeling medium containing
100 μCi/ml [35S]methionine/cysteine (Hartmann Ana-
lytics, Braunschweig, Germany). For the chase, cells
were incubated for an additional 2 h in complete
DMEM. Cells were lysed in PBS, 1% Triton X-100,
0.5% deoxycholate, and 2 mM phenylmethylsulfonyl
fluoride for 1 h at 4 °C, scraped, and centrifuged for
10 min in a microfuge. Media were collected and
centrifuged for 15 min at 3000 × g. Supernatants were
supplemented with an equal volume of 2X lysis buf-
fer. Immunoprecipitation was performed using the
anti-NPII antiserum and protein A Sepharose. Sam-
ples were boiled in SDS sample buffer containing
100 mM DTT and analyzed by 10% polyacrylamide
Tris/tricine SDS-gel electrophoresis and autoradiog-
raphy using a phosphorimager.
Stimulated secretion
AtT20 cells stably expressing wild-type or mutant prova-
sopressin or A1Pi were grown in 10-cm dishes, washed
with PBS, and then incubated for 30 min in 3 ml secre-
tion medium (Earle’s balanced salt solution without Ca2+
and Mg2+, supplemented with MEM amino acids,
2 mM L-glutamine, MgSO4, and 2 mM CaCl2; Sigma).
After collecting the media, the cells were washed with
PBS and incubated for another 30 min in stimulation
medium (secretion medium without CaCl2, but contain-
ing 2 mM BaCl2). Collected secretion and stimulation
media were centrifuged for 15 min at 3000 × g, and the
supernatants were concentrated using Amicon Ultra-2
(molecular weight cut-off 3 kDa; Millipore). Samples
were analyzed by immunoblotting.
Electron microscopy
Cultured cells were fixed in 3% formaldehyde and 0.2%
glutaraldehyde for 2 h at room temperature. Cells were
then scraped, pelleted, resuspended, and washed three
times in PBS, incubated with 50 mM NH4Cl in PBS for
30 min, washed three times in PBS, resuspended in 2%
warm agarose, and left to solidify on ice. Agarose pieces
were dehydrated and infiltrated with LR gold resin
(London Resin, London, UK) and allowed to polymerize
for 1 day at −10 °C. For immunogold labeling, sections
of 60–70 nm were collected on carbon-coated Formvar-
Ni-grids, incubated with our rabbit anti-provasopressin,
with a rabbit anti-myc antibody (Abcam, Ab-9106, RRI-
D:AB_307014) or with rabbit anti-calreticulin antibody
(Stressgen, SPA-600, Lot: 004417, RRID:AB_10618853)
in PBS, 2% BSA, 0.1% Tween-20 for 2 h, washed with
PBS, and incubated with 10-nm colloidal gold-
conjugated goat anti-rabbit immunoglobulin antibodies
(BB International, EM GAR10, RRID:AB_1769128,
1:100) in PBS, 2% BSA, and 0.1% Tween-20 for 90 min.
Grids were washed five times for 5 min in PBS and then
five times in H2O, before staining for 10 min in 2% ur-
anyl acetate. Sections were viewed with a Phillips
CM100 electron microscope.
Additional files
Additional file 1: Figure S1.. Localization of wild-type provasopressin
and the ΔE47 DI mutant in transfected HN10 cells. Immunofluorescence
localization of wild-type (wt)
provasopressin and the DI mutant precursor ΔE47 expressed in HN10
cells 48 h after transfection. Cells were costained with antibodies against
provasopressin (V; blue), KDEL as an ER marker (red), and CgA as a cargo
of secretory granules (green). Wild-type provasopressin is detected in
granules in the neuronal extension together with CgA (filled arrowheads),
whereas ΔE47 in a majority of expressing cells is found in aggregates in
the ER of the cell body costained with anti-KDEL (open arrowheads). Bar:
10 μm. (TIF 1759 kb)
Additional file 2: Figure S2.. The second aggregation motif also causes
fibrillar aggregation. A–D Electron microscopy of Pro1 (A and B) or
ΔE47Pro1 (C and D) decorated with immunogold for provasopressin
(A, C, and D) or for calreticulin (B). The ΔE47 point mutation made no
observable difference in the range of aggregate morphologies. Bars:
500 nm. (TIF 9565 kb)
Additional file 3: Figure S3.. Vasopressin residues binding into NPII.
NPII (blue) with bound vasopressin (green) is shown according to the
crystal structure 1JK4 [1]. Residues P7, R8, and G9, which were not
resolved in the structure, are presented in an arbitrary conformation. On
the right, the portion of vasopressin interacting with NPII is shown in
blue. (TIF 520 kb)
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